# Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

> **NCT07489066** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Pfizer** · enrollment: 120 (estimated)

## Conditions studied

- Carcinoma
- Non-Small-Cell Lung
- Lung Cancer (NSCLC)
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung (NSCLC)
- Lung Disease
- Non-Small Cell Lung Cancer
- Non-small Cell Lung Cancer, Non-squamous
- Non-small Cell Lung Cancer, Squamous

## Interventions

- **BIOLOGICAL:** PF-08634404
- **DRUG:** Chemotherapy Regimen 1
- **DRUG:** Chemotherapy Regimen 2

## Key facts

- **NCT ID:** NCT07489066
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2028-08-04
- **Final completion:** 2031-08-05
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07489066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07489066, "Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT07489066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*